PMC:7536913 / 10473-10797 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T29","span":{"begin":134,"end":181},"obj":"Disease"},{"id":"T30","span":{"begin":134,"end":167},"obj":"Disease"},{"id":"T31","span":{"begin":183,"end":187},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T54","span":{"begin":102,"end":105},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":23,"end":27},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"92","span":{"begin":134,"end":181},"obj":"Species"},{"id":"93","span":{"begin":315,"end":323},"obj":"Species"},{"id":"95","span":{"begin":183,"end":192},"obj":"Species"}],"attributes":[{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"Tax:9606"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T70","span":{"begin":0,"end":324},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients."}